These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30638863)

  • 1. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
    Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
    Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
    J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CD8
    Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
    Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N;
    Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
    Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
    Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
    Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD;
    Lancet Respir Med; 2019 Nov; 7(11):951-963. PubMed ID: 31582358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
    Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
    JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
    Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
    Whitley R; Laughlin A; Carson S; Mitha E; Tellier G; Stich M; Elder J; Alexander WJ; Dobo S; Collis P; Sheridan WP
    Antivir Ther; 2015; 20(7):709-19. PubMed ID: 25318121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
    Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
    J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.